S. Bailly, N. Daabek, I. Jullian-desayes, M. Joyeux-faure, M. Sapéne, Y. Grillet, J. Borel, R. Tamisier, J. Pépin
{"title":"Factors Associated with Residual Events in CPAP-Treated Sleep Apnea: Data from a Large French National Database","authors":"S. Bailly, N. Daabek, I. Jullian-desayes, M. Joyeux-faure, M. Sapéne, Y. Grillet, J. Borel, R. Tamisier, J. Pépin","doi":"10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2867","DOIUrl":null,"url":null,"abstract":"Introduction & background: Residual events during CPAP contribute to increase treatment drop-outs. Clinical scenarios triggering residual events during CPAP use are poorly described. Aims & objectives: Underlying comorbidities, especially cardiovascular diseases, lifestyle factors, OSA characteristics at baseline and type of mask are suggested as potential contributors. Methods: Patients from the prospective national French sleep apnea registry with apnea-hypopnea index (AHI) = 15/h and CPAP indication were included. A logistic regression analysis was used to identify factors associated with the probability of exhibiting a residual AHI > 5/h whilst on CPAP. Results: 12,285 OSA patients predominantly men (N=8715, 70.9%), middle aged (median [IQR]: 58.2 [49.8;66.1] years) and obese (median body mass index: 31.3 [27.7;35.6] kg/m²) were included. Most had an AHI=5/h (N=9,573, 77.9%) versus 22.1% exhibited an AHI>5/hour. The latter group was significantly less adherent to CPAP (5.75 [4.01;7.00] vs 6.00 [4.53;7.00] h/night). In multivariable analysis, factors associated with a high residual AHI were male gender, age and sedentary lifestyle, OSA severity, cardiovascular comorbidities and interface (orofacial versus nasal mask: OR = 2.15 [CI: 1.95;2.37]). Conclusions: The knowledge of at-risk clinical scenarios predicting more frequent residual events will help in the timely provision of personalized care including type of PAP therapy, attention to comorbidity care and interfacechoice","PeriodicalId":305670,"journal":{"name":"B30. SRN: BIG DATA ANALYSIS AND POPULATION BASED STUDIES","volume":"70 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"B30. SRN: BIG DATA ANALYSIS AND POPULATION BASED STUDIES","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2867","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction & background: Residual events during CPAP contribute to increase treatment drop-outs. Clinical scenarios triggering residual events during CPAP use are poorly described. Aims & objectives: Underlying comorbidities, especially cardiovascular diseases, lifestyle factors, OSA characteristics at baseline and type of mask are suggested as potential contributors. Methods: Patients from the prospective national French sleep apnea registry with apnea-hypopnea index (AHI) = 15/h and CPAP indication were included. A logistic regression analysis was used to identify factors associated with the probability of exhibiting a residual AHI > 5/h whilst on CPAP. Results: 12,285 OSA patients predominantly men (N=8715, 70.9%), middle aged (median [IQR]: 58.2 [49.8;66.1] years) and obese (median body mass index: 31.3 [27.7;35.6] kg/m²) were included. Most had an AHI=5/h (N=9,573, 77.9%) versus 22.1% exhibited an AHI>5/hour. The latter group was significantly less adherent to CPAP (5.75 [4.01;7.00] vs 6.00 [4.53;7.00] h/night). In multivariable analysis, factors associated with a high residual AHI were male gender, age and sedentary lifestyle, OSA severity, cardiovascular comorbidities and interface (orofacial versus nasal mask: OR = 2.15 [CI: 1.95;2.37]). Conclusions: The knowledge of at-risk clinical scenarios predicting more frequent residual events will help in the timely provision of personalized care including type of PAP therapy, attention to comorbidity care and interfacechoice